253 related articles for article (PubMed ID: 24529932)
1. Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study.
Werner M; Micari A; Cioppa A; Vadalà G; Schmidt A; Sievert H; Rubino P; Angelini A; Scheinert D; Biamino G
JACC Cardiovasc Interv; 2014 Mar; 7(3):305-12. PubMed ID: 24529932
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
Werner M; Schmidt A; Scheinert S; Banning-Eichenseer U; Ulrich M; Bausback Y; Steiner S; Scheinert D
J Endovasc Ther; 2016 Feb; 23(1):92-7. PubMed ID: 26620399
[TBL] [Abstract][Full Text] [Related]
3. Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.
Nishio S; Kosuga K; Igaki K; Okada M; Kyo E; Tsuji T; Takeuchi E; Inuzuka Y; Takeda S; Hata T; Takeuchi Y; Kawada Y; Harita T; Seki J; Akamatsu S; Hasegawa S; Bruining N; Brugaletta S; de Winter S; Muramatsu T; Onuma Y; Serruys PW; Ikeguchi S
Circulation; 2012 May; 125(19):2343-53. PubMed ID: 22508795
[TBL] [Abstract][Full Text] [Related]
4. Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents: single-center experience.
Silingardi R; Lauricella A; Coppi G; Nicolosi E; Gennai S; Coppi G
J Vasc Interv Radiol; 2015 Mar; 26(3):374-81.e1. PubMed ID: 25636670
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery: prospective and multicentric trial.
Nasser F; Kambara A; Abath C; Cavalcanti D; Barros I; Pires N; Rivera M; Neser A; Ingrund J; Burihan M; Silveira P; Galego G; Bortoluzzi C; Franklin R; Bosiers M; Deloose K; Razuk A; Caffaro R; Karakhanian WK; Park J; Lopes C; Pinto D; Bez L; Lopes R; Mourão A; Kleinsorge G
J Cardiovasc Surg (Torino); 2017 Jun; 58(3):409-415. PubMed ID: 25731858
[TBL] [Abstract][Full Text] [Related]
6. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
[TBL] [Abstract][Full Text] [Related]
7. A great start, but the promise of biodegradable stents remains to be proven.
Katzen BT
JACC Cardiovasc Interv; 2014 Mar; 7(3):313-4. PubMed ID: 24529935
[No Abstract] [Full Text] [Related]
8. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT).
Zeller T; Tiefenbacher C; Steinkamp HJ; Langhoff R; Wittenberg G; Schlüter M; Buergelin K; Rastan A; Krumsdorf U; Sixt S; Schulte CL; Tübler T; Krankenberg H
J Endovasc Ther; 2008 Aug; 15(4):390-8. PubMed ID: 18729564
[TBL] [Abstract][Full Text] [Related]
9. Endovascular treatment of long lesions of the superficial femoral artery: results from a multicenter registry of a spiral, covered polytetrafluoroethylene stent.
Lenti M; Cieri E; De Rango P; Pozzilli P; Coscarella C; Bertoglio C; Troiani R; Cao P
J Vasc Surg; 2007 Jan; 45(1):32-9. PubMed ID: 17210380
[TBL] [Abstract][Full Text] [Related]
10. Non-randomized, prospective, multi-centre evaluation of the ABSOLUTE .035 peripheral self-expanding stent system for occluded or stenotic superficial femoral or proximal popliteal arteries (ASSESS Trial): acute and 30-day results.
Zeller T; Saratzis N; Scheinert D; Minar E; Beregi JP; Schillinger M; Hausegger HA; Amor M; Quaretti P; Moratto R; Dorange C; Boone E; Krankenberg H
J Cardiovasc Surg (Torino); 2007 Dec; 48(6):719-26. PubMed ID: 17947929
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month results of percutaneous endovascular reconstruction for chronically occluded superficial femoral arteries: a quality-of-life assessment.
Dippel E; Shammas N; Takes V; Coyne L; Lemke J
J Invasive Cardiol; 2006 Jul; 18(7):316-21. PubMed ID: 16816437
[TBL] [Abstract][Full Text] [Related]
12. Outcome benefit of arterial duplex stent imaging after superficial femoral artery stent implantation.
Draxler MS; Al-Adas Z; Abbas D; Kavousi Y; Kabbani LS; Lin JC; Weaver MR; Shepard AD; Nypaver TJ
J Vasc Surg; 2021 Jan; 73(1):179-188. PubMed ID: 32437951
[TBL] [Abstract][Full Text] [Related]
13. One-year outcomes for recanalization of long superficial femoral artery chronic total occlusions with the Viabahn stent graft.
Farraj N; Srivastava A; Pershad A
J Invasive Cardiol; 2009 Jun; 21(6):278-81. PubMed ID: 19494404
[TBL] [Abstract][Full Text] [Related]
14. Duplex criteria for determination of in-stent stenosis after angioplasty and stenting of the superficial femoral artery.
Baril DT; Rhee RY; Kim J; Makaroun MS; Chaer RA; Marone LK
J Vasc Surg; 2009 Jan; 49(1):133-8; discussion 139. PubMed ID: 19174252
[TBL] [Abstract][Full Text] [Related]
15. [Use of stents with bioactive coating in treatment of patients with lesions of the superficial femoral artery].
Generalov MI; Maĭstrenko DN; Oleshchuk AN; Ivanov AS; Granov DA; Ovchinnikov IV; Khmel'nitskiĭ AV; Gusinskiĭ AV
Angiol Sosud Khir; 2016; 22(3):59-64. PubMed ID: 27626251
[TBL] [Abstract][Full Text] [Related]
16. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty.
Gray BH; Sullivan TM; Childs MB; Young JR; Olin JW
J Vasc Surg; 1997 Jan; 25(1):74-83. PubMed ID: 9013910
[TBL] [Abstract][Full Text] [Related]
17. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
18. PTFE-covered self-expanding nitinol stents for the treatment of severe iliac and femoral artery stenoses and occlusions: final results from a prospective study.
Wiesinger B; Beregi JP; Oliva VL; Dietrich T; Tepe G; Bosiers M; Hüttl K; Müller-Hülsbeck S; Bray A; Tielemans H; Duda SH
J Endovasc Ther; 2005 Apr; 12(2):240-6. PubMed ID: 15823072
[TBL] [Abstract][Full Text] [Related]
19. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA "STEnting Long de L'Artère fémorale superficielle" cohort).
Davaine JM; Azéma L; Guyomarch B; Chaillou P; Costargent A; Patra P; Lambert G; Gouëffic Y
Eur J Vasc Endovasc Surg; 2012 Oct; 44(4):432-41. PubMed ID: 22920949
[TBL] [Abstract][Full Text] [Related]
20. The role of superficial femoral artery endoluminal bypass in long de novo lesions and in-stent restenosis.
Doomernik DE; Golchehr B; Lensvelt MM; Reijnen MM
J Cardiovasc Surg (Torino); 2012 Aug; 53(4):447-57. PubMed ID: 22854524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
